• The first GLP-1/amylin combination is days from an FDA decision. Novo Nordisk submitted the NDA for CagriSema in December 2025. If approved, it will be the first drug to combine GLP-1 and amylin receptor agonism in a single weekly injection, delivering 20.4% weight loss at 68 weeks under the treatment-policy estimand (and up to 23% among on-treatment completers) — roughly five percentage points beyond what semaglutide achieves alone.
• This is not one drug. It's a drug class. Forty amylin receptor agonist programs are in development worldwide. They span every modality: injectable peptides, oral peptides, oral small molecules, monoclonal antibodies. They include pure amylin agonists, dual amylin/calcitonin agonists, GLP-1/amylin unimolecular fusions, and triple-target combinations. Most investors can name one.

• Amylin is the only validated mechanism that adds weight loss on top of GLP-1. CagriSema's Phase 3 data (REDEFINE 1) showed 20.4% weight loss. Amycretin's Phase 2 showed 14.5% in type 2 diabetes patients already on metformin. Eloralintide's Phase 2 showed up to 20.1% as a pure amylin monotherapy. These are not incremental improvements. They represent the first evidence that the GLP-1 efficacy ceiling can be broken.
• More than $19 billion has been committed since 2024. Pfizer paid $10 billion for Metsera. Roche paid $5.3 billion for petrelintide. AbbVie committed $2.2 billion for Gubra's DACRA. Pfizer committed another $2.5 billion for Sciwind's amylin pipeline. Every major pharma company except Merck is now building an amylin position.
• The field learned its lessons from failure. Pramlintide (the first and only approved amylin analog) was a commercial flop: three-times-daily dosing, poor tolerability, modest weight loss. Davalintide was discontinued. The current generation has been re-engineered from the ground up: long-acting formulations enabling weekly dosing, combination strategies that multiply efficacy, and tolerability profiles that rival placebo.
• Oral small-molecule amylin agonists are arriving. Structure Therapeutics initiated the first-in-human study of ACCG-2671 in December 2025 — the first oral small-molecule amylin agonist ever to enter clinical development. If oral GLP-1 small molecules unlocked 95% of the untreated market, oral amylin small molecules could do the same for the combination market.
• Patent depth varies wildly, and it matters more than most analysis acknowledges. Petrelintide has composition-of-matter protection through 2037, extendable to 2042. CagriSema's amylin component ties to semaglutide patents expiring in 2031. The oral small-molecule space is largely unpatented. When efficacy converges, IP architecture is what separates franchises from commodities.
• The next eighteen months will reshape the landscape. CagriSema FDA decision, eloralintide Phase 3 data, petrelintide ZUPREME-2 readout, amycretin Phase 3 initiation, ACCG-2671 Phase 1 data, and Viking Therapeutics' DACRA IND are all expected by late 2027. More catalysts in eighteen months than in the previous five years.

1.0 A Quick Orientation

This report is written for investors, business development professionals, and anyone evaluating the obesity drug landscape beyond GLP-1. If you are already fluent in amylin biology, receptor pharmacology, and the competitive dynamics of the obesity market, skip to Section 3. If not, this section gives you just enough to follow the rest.

• Amylin (IAPP). A 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to meals. Amylin signals through the area postrema and nucleus tractus solitarius in the brainstem, promoting satiety, slowing gastric emptying, and suppressing postprandial glucagon secretion. In obese patients, amylin signaling is blunted — analogous to leptin resistance. Restoring amylin signaling reduces food intake through neural pathways that are complementary to, but distinct from, GLP-1.
• GLP-1 receptor agonist (GLP-1 RA). A drug that activates the GLP-1 receptor, mimicking the natural incretin hormone GLP-1. Drives insulin secretion, appetite suppression, and weight loss. Semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are the dominant commercial products, collectively generating over $71 billion in annual revenue. The market is growing but the mechanism is approaching a pharmacological ceiling for monotherapy weight loss.
• Amylin receptor pharmacology. Amylin does not bind a single receptor. It activates a family of receptors formed by the calcitonin receptor (CALCR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). This creates three receptor subtypes — AMY1R, AMY2R, AMY3R — with distinct tissue distributions and signaling profiles. Some amylin drugs are selective for AMYR (amylin receptor only), while others are DACRAs (dual amylin and calcitonin receptor agonists), activating both AMYR and CALCR. This selectivity distinction has clinical consequences: pure AMYR agonists may have cleaner safety profiles, while DACRAs may achieve greater efficacy through broader receptor engagement.

• Pramlintide (Symlin). The first and only amylin analog ever approved by the FDA (2005). A synthetic analog of human amylin for type 2 diabetes, dosed three times daily via injection before meals. Pramlintide delivered modest weight loss (2-3 kg), caused significant nausea, and was a commercial failure. All three formulations have been discontinued. Its patents expired between 2013-2019. Pramlintide proved the mechanism works. It also proved that first-generation amylin analogs were not good enough.
• CagriSema. Novo Nordisk's fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 RA) in a single once-weekly injection. NDA filed December 2025. This is the most advanced amylin-containing drug in the world and the first to combine both mechanisms in one product.
• DACRA (Dual Amylin and Calcitonin Receptor Agonist). A compound that activates both amylin and calcitonin receptors. Several programs (GUB-014295/AbbVie, Viking's preclinical DACRA, cagrilintide itself) use this approach. Broader receptor engagement may drive stronger appetite suppression but also introduces calcitonin-related safety monitoring requirements (C-cell hyperplasia, thyroid concerns).
• Placebo-adjusted body weight loss (BWL). The standard efficacy metric. If drug patients lose 22% and placebo patients lose 2%, the placebo-adjusted BWL is 20%. Cross-trial comparisons are imprecise because trials differ in duration, patient population, baseline BMI, and dosing. But the broad patterns are meaningful.
• Deal economics. When we describe a "$10 billion" or "$5.3 billion" deal, that is almost always total potential value: upfront cash plus development and sales milestones paid if specific events occur. The true committed capital at signing is the upfront. For Pfizer/Metsera, the final price was $10 billion total after a bidding war. For Roche/Zealand, the upfront was $1.65 billion of the $5.3 billion headline.

With these building blocks in place, we can talk about what actually matters: why amylin, why now, and who is building what.

2.0 The Thirty-Year Overnight Success

The pharmaceutical industry spent thirty years trying to make amylin work. It didn't. Then everything changed at once.

Amylin was discovered in 1987 by Garth Cooper and colleagues at the University of Auckland, identified as a 37-amino-acid peptide found in amyloid deposits in the pancreatic islets of type 2 diabetes patients. The biology was immediately compelling: amylin is co-secreted with insulin after meals, signals satiety through the brainstem, slows gastric emptying, and suppresses glucagon. It was the body's other appetite hormone, operating through neural circuits completely separate from the incretin pathway that GLP-1 agonists would later exploit.

The problem was the molecule itself.

Native human amylin is a pharmaceutical nightmare. It aggregates into amyloid fibrils in solution, rendering it unstable for formulation. It has a plasma half-life of approximately 13 minutes, requiring multiple daily injections. And the therapeutic window between efficacy and nausea is narrow — the same brainstem circuits that suppress appetite also trigger vomiting when overstimulated.

Amylin Pharmaceuticals (founded 1987, San Diego) spent fifteen years and over $1 billion trying to solve these problems. The result was pramlintide (Symlin), a synthetic analog with three proline substitutions at positions 25, 28, and 29 that prevented amyloid aggregation. The FDA approved it in 2005 for type 2 diabetes as an adjunct to insulin.

Pramlintide was a scientific proof of concept and a commercial failure. It required injection before every meal — three times daily. Nausea occurred in 30-50% of patients. Weight loss was modest: 2-3 kg over 12 months. At peak, Symlin generated roughly $100 million in annual revenue, a rounding error in the diabetes market. Bristol-Myers Squibb acquired Amylin Pharmaceuticals in 2012 for $5.3 billion, driven primarily by the GLP-1 program exenatide (Byetta/Bydureon), not pramlintide. All Symlin formulations have since been discontinued.

The next attempt fared worse. Davalintide, a second-generation amylin analog also from Amylin Pharmaceuticals, entered Phase 2 in the late 2000s for obesity. The efficacy-to-tolerability ratio was unfavorable, and the program was discontinued. Amylin Pharmaceuticals pivoted to a pramlintide/metreleptin combination for Phase 3 instead — a combination that also ultimately failed to reach market.

By 2015, the consensus was clear: amylin was an interesting piece of biology with an intractable drug development problem. GLP-1 agonists were delivering 15-22% weight loss with weekly dosing. Why bother with a hormone that required three daily injections and made patients vomit?

Three things changed.

2.1 The Long-Acting Engineering Revolution

The first breakthrough was molecular engineering. Between 2014 and 2022, peptide chemists at Novo Nordisk, Eli Lilly, and Zealand Pharma independently solved the half-life problem through acylation — attaching fatty acid side chains to the amylin peptide backbone that enable albumin binding in circulation, extending the half-life from minutes to days.

Cagrilintide (Novo Nordisk) was the first to demonstrate this. Designed as a 36-amino-acid acylated analog with a lipophilic side chain enabling weekly dosing, cagrilintide entered Phase 1 in December 2014. It was the first amylin analog that could be dosed once a week instead of three times a day. This single change converted amylin from an impractical adjunct therapy into something that could compete with injectable GLP-1 agonists on convenience.

Petrelintide (Zealand Pharma) achieved an even longer half-life — approximately 10 days — through a different acylation strategy, also enabling once-weekly dosing. Eloralintide (Eli Lilly) used yet another approach: a C-terminally amidated 37-amino-acid polypeptide with a methylene thioacetal bond and a dual gamma-glutamic acid acylation strategy.

Three companies, three independent solutions to the same problem, all converging in the same timeframe. The half-life barrier that killed pramlintide's commercial viability was gone.

2.2 The Combination Thesis

The second breakthrough was strategic, not molecular. Between 2019 and 2023, clinical data from cagrilintide+semaglutide combination studies demonstrated something that fundamentally changed the competitive calculus: amylin and GLP-1 are synergistic, not merely additive.

In a Phase 2 trial, the combination of cagrilintide and semaglutide (later branded CagriSema) achieved 15.6% weight loss at 32 weeks, compared to 5.1% for semaglutide alone. The incremental benefit of adding amylin — roughly 10 percentage points — was larger than the benefit of semaglutide itself. This was not a marginal improvement. It was evidence that amylin activates weight-loss pathways that GLP-1 cannot reach.

The mechanistic explanation is now well-characterized. GLP-1 agonists primarily suppress appetite through hypothalamic circuits and enhance insulin secretion through pancreatic beta cells. Amylin agonists primarily signal through the area postrema and nucleus tractus solitarius in the dorsal vagal complex — the brainstem's energy balance hub. The two pathways converge on appetite suppression but through overlapping yet distinct neural populations. Activating both simultaneously produces a compounding effect that neither can achieve alone.

This is not theoretical pharmacology. It is the basis for a $19 billion M&A wave.

2.3 The Tolerability Breakthrough

The third change was the emergence of amylin analogs with dramatically improved tolerability. Petrelintide's Phase 2 ZUPREME-1 data, announced on March 5, 2026, was the clearest signal yet: 10.7% weight loss at 42 weeks with what Zealand described as a "placebo-like" safety profile. Zero vomiting events. Zero GI-related discontinuations at the maximally effective dose. The adverse-event discontinuation rate was 4.8% — virtually identical to placebo at 4.9%.

This is a different drug class than what pramlintide represented. The tolerability problem that killed the first generation has been engineered out of the current one.

Eloralintide told a similar story at a different efficacy level. Eli Lilly's Phase 2 data showed up to 20.1% weight loss at 48 weeks across a dose range, with a tolerability profile consistent with the selective amylin agonist design — targeting AMYR with minimal CALCR activation, theoretically reducing the calcitonin-related side effects that broader-acting DACRAs might cause.

AbbVie's ABBV-295 (licensed from Gubra) reported Phase 1 multiple-ascending-dose data showing 7.75% to 9.79% weight loss at just 12 weeks, with dose-dependent efficacy and good tolerability. For a Phase 1 readout, that trajectory is steep.

The convergence of long-acting engineering, combination synergy, and improved tolerability has turned amylin from a failed first-generation mechanism into the second pillar of obesity medicine. The question is no longer whether amylin works. It's who owns it.

3.0 Forty Programs and Counting

Most investors tracking the obesity space can name CagriSema. Some can name two or three amylin programs. Almost nobody knows what's actually behind it.

There are approximately forty amylin receptor agonist programs in development worldwide, spanning every stage from NDA filing through preclinical discovery. The pipeline has grown 167% in four years, from roughly 15 programs in 2022 to 40 in early 2026.

Read that list carefully. Novo Nordisk has at least six amylin programs in development simultaneously: CagriSema, cagrilintide as a standalone, amycretin, NN-9490, NN1213, and NNC0638-0355. Eli Lilly has eloralintide in Phase 3 with combination studies planned. Roche paid $5.3 billion for access to petrelintide. Pfizer spent $10 billion acquiring Metsera and $2.5 billion licensing Sciwind's amylin pipeline. AbbVie committed $2.2 billion for Gubra's DACRA. AstraZeneca has AZD6234 in Phase 2. Structure Therapeutics has the first oral small-molecule amylin agonist in clinical development plus a backup (ACCG-3535) in preclinical. Viking Therapeutics is filing its DACRA IND.

When Novo, Lilly, Roche, Pfizer, AbbVie, AstraZeneca, and Structure are all building amylin positions simultaneously, this is not a niche. It is the next standard of care.

The diversity of approaches is striking. Unlike the oral GLP-1 landscape where programs converge on similar chemical scaffolds, the amylin pipeline spans radically different drug modalities:

This modality diversity means the amylin race is not just about which molecule wins. It's about which format wins for which patient population. The injectable peptides will compete at the top of the efficacy curve. The oral small molecules will compete on convenience and cost. The unimolecular fusions will compete on manufacturing simplicity. And the combinations — amylin + GLP-1, amylin + GLP-1 + GIP, amylin + glucagon — will compete for the patients who need maximum weight loss and are willing to accept the complexity.

4.0 The Programs That Matter Most

The fourteen programs that have advanced to Phase 2 or beyond are the ones to watch closest. Here's what separates them.

4.1 NDA Stage

One program has reached NDA filing.

CagriSema: Novo Nordisk

CagriSema is the furthest-advanced amylin-containing drug in the world and the product that will validate or undermine the entire amylin investment thesis.

The clinical data is strong. REDEFINE 1 (Phase 3, obesity without diabetes) delivered 20.4% mean weight loss at 68 weeks under the treatment-policy estimand (approximately 23% among on-treatment completers) — roughly five percentage points beyond what semaglutide achieves alone. REDEFINE 2 (Phase 3, obesity with type 2 diabetes) showed 15.7% weight loss versus 3.1% for placebo, with 91.9% of patients achieving at least 5% body weight reduction. Earlier Phase 2 data showed 15.6% weight loss for the combination versus 5.1% for semaglutide alone — confirming the synergy thesis with an approximately 10 percentage point incremental benefit from adding amylin.

The safety profile carries the expected GI burden: nausea in 30-50% of patients, vomiting in 10-20%, though most events are mild-to-moderate and resolve with titration. The calcitonin receptor engagement from cagrilintide introduces monitoring requirements for C-cell hyperplasia that do not apply to pure amylin agonists. Pancreatitis surveillance (lipase monitoring) is required.

The commercial thesis is straightforward. CagriSema is positioned as the upgrade for patients who have maxed out on GLP-1 monotherapy and want more weight loss. At an expected price of $200-300/month (a premium over semaglutide's $150-200/month), peak sales estimates range from $2.5 billion to $4.0 billion annually.

The IP question is more nuanced. CagriSema is a two-component combination: cagrilintide plus semaglutide. Semaglutide's core composition-of-matter patent expires in December 2031. Cagrilintide has its own patent protection, and the combination itself is patented, but the semaglutide component creates a clock. When semaglutide goes generic in 2032, the value proposition of a combination product containing a generic-available component shifts. Patent-term extension could push practical exclusivity into the mid-2030s, but the timeline is compressed relative to competitors with later-expiring standalone composition-of-matter patents.

CagriSema's approval, expected late 2026, will be the single most important catalyst in the amylin space. Approval validates amylin as a commercial mechanism and accelerates every program behind it. Rejection or significant delay would force a recalibration of the entire pipeline's timeline and deal valuations.

4.2 Phase 3

Three programs are in Phase 3, each with a distinct competitive thesis.

Eloralintide (LY3841136): Eli Lilly

Eloralintide is Eli Lilly's entry into the amylin space and the most efficacious pure amylin monotherapy in development. Phase 2 data (263 adults with obesity, 48 weeks) showed a dose-dependent range of 9.5% to 20.1% mean weight reduction, compared to 0.4% for placebo. At the highest dose, 20.1% weight loss from a pure amylin agonist — without any GLP-1 component — is a remarkable result.

The mechanism is deliberately selective. Eloralintide targets the amylin receptor with 50-100x selectivity over CALCR, minimizing the calcitonin-related safety signals that dual AMYR/CALCR agonists like cagrilintide must monitor. This selectivity thesis predicts a cleaner safety profile: lower nausea incidence (estimated 15-30% versus 30-50% for triple-target agents), reduced C-cell hyperplasia concern, and potentially better long-term tolerability.

Phase 3 was initiated in early 2026 for both monotherapy and combination use with incretin therapy. Lilly's strategic play is clear: eloralintide as a standalone for patients who don't tolerate GLP-1s, and eloralintide + tirzepatide as a combination for maximum efficacy. Given that Lilly already owns tirzepatide (the dual GLP-1/GIP agonist behind Zepbound), a tirzepatide + eloralintide combination would create a triple-mechanism product — GLP-1 + GIP + amylin — without requiring the regulatory complexity of reformulating three peptides into a single product.

Peak sales estimates: $800 million to $1.5 billion as a standalone, significantly more if the tirzepatide combination succeeds.

Amycretin (NN9487): Novo Nordisk

Amycretin represents a fundamentally different engineering approach. Instead of combining two separate peptides (like CagriSema), amycretin is a single molecule — a unimolecular dual agonist that activates both GLP-1R and AMYR from a single peptide backbone. This is architecturally simpler: one manufacturing process instead of two, one stability profile instead of two, one dose-optimization challenge instead of two.

Phase 2 data (November 2025, 448 patients with type 2 diabetes) showed 14.5% weight loss for the injectable formulation and 10.1% for the oral formulation at 36 weeks. HbA1c reduction was 1.6% for injectable and 1.1% for oral. These numbers are in a type 2 diabetes population (which typically shows lower weight loss than obesity-only populations), making direct comparison to CagriSema's REDEFINE data difficult.

The oral formulation is the strategic headline. If amycretin can deliver meaningful weight loss as an oral pill, it would be the first oral GLP-1/amylin combination — potentially the most commercially valuable drug format in the obesity space. Phase 3 initiation is planned for 2026, with potential approval in the 2028-2029 timeframe.

Peak sales estimates: $1.2-2.0 billion, significantly more if the oral formulation succeeds.

4.3 Phase 2

Five programs are in Phase 2, and the data emerging from this tier is reshaping expectations for what amylin agonists can achieve.

Petrelintide (ZP8396): Zealand Pharma / Roche

Petrelintide's ZUPREME-1 data (announced March 5, 2026) may be the most strategically important readout in the amylin landscape this year. Not for the weight loss number — 10.7% at 42 weeks is moderate — but for the tolerability profile.

Zero vomiting events at the maximally effective dose. Zero GI-related discontinuations. The overall adverse-event discontinuation rate of 4.8% was virtually identical to placebo (4.9%). Zealand described the profile as "placebo-like."

This matters because tolerability is the bottleneck that limits amylin drug adoption. Pramlintide failed commercially because patients couldn't tolerate it. GLP-1 agonists lose 10-20% of patients to GI side effects. If petrelintide can deliver meaningful weight loss with no vomiting, it addresses the single largest barrier to amylin market penetration.

The efficacy number (10.7%) is lower than eloralintide (20.1%) or CagriSema (20.4%), but the comparison is imprecise — different doses, durations, and populations. More importantly, petrelintide is being developed as a combination partner with Roche's CT-388 (a GLP-1/GIP dual agonist). A Phase 2 combination trial initiated in H1 2026. The relevant question is not whether petrelintide monotherapy matches CagriSema's weight loss, but whether petrelintide + CT-388 can match or exceed CagriSema's efficacy with superior tolerability.

The deal structure reflects this thesis. Roche paid $1.65 billion upfront (including a $250 million signing bonus) plus up to $3.65 billion in milestones, totaling $5.3 billion. This makes petrelintide the single largest amylin-specific deal in history.

The IP position is the strongest in the space. Petrelintide's composition-of-matter patents expire in 2037, with patent-term extension available for up to five additional years, potentially extending protection to 2042. This is a decade longer than CagriSema's semaglutide component expires.

4.4 Phase 1

Eight programs are in Phase 1. Three stand out.

ACCG-2671: Structure Therapeutics

This is the program that could change the format of the entire amylin space. ACCG-2671 is the first oral small-molecule amylin receptor agonist ever to enter clinical development. Structure Therapeutics initiated the first-in-human Phase 1 study on December 17, 2025.

ACCG-2671 is a DACRA — a dual amylin and calcitonin receptor agonist — but in a small-molecule format designed for once-daily oral dosing. Preclinical data showed potent target engagement, robust weight loss as monotherapy, and enhanced weight loss when combined with a GLP-1 receptor agonist. The safety and pharmacokinetic profile supports once-daily oral dosing without food restrictions.

The commercial implications mirror what oral small-molecule GLP-1 agonists represent for the GLP-1 market. Injectable amylin peptides like cagrilintide and petrelintide will compete at the top of the efficacy curve. But an oral amylin small molecule at $5-15/month manufacturing cost could reach the 95% of patients who will never inject. And an oral amylin combined with an oral GLP-1 — a daily pill targeting both pathways — could be the ultimate convenience product for primary care.

Structure also has ACCG-3535 in preclinical development as a backup oral small-molecule DACRA, demonstrating platform capability rather than single-asset risk.

Phase 1 data is expected H2 2026. If the safety and PK data support advancement, this program could reshape the competitive landscape.

GUB-014295 (ABBV-295): AbbVie / Gubra

AbbVie's entry into amylin came via a $2.225 billion deal with Gubra (March 2025, $350 million upfront). GUB-014295 is a long-acting amylin analog — a DACRA — in Phase 1.

The Phase 1 multiple-ascending-dose data is impressive for this early stage: 7.75% to 9.79% weight loss at just 12 weeks, with dose-dependent efficacy and good tolerability. For context, orforglipron (the leading oral GLP-1 agonist, now at NDA) showed approximately 6-8% weight loss at comparable early timepoints. If GUB-014295's trajectory holds, the 52-week efficacy could be substantial.

MET-233: Pfizer / Metsera

MET-233 is a monthly amylin analog — the longest-dosing-interval amylin agonist in development. Pfizer acquired Metsera in November 2025 for $10 billion after a bidding war with Novo Nordisk, the largest amylin-related acquisition in history.

The Metsera platform includes MET-233 (monthly amylin, Phase 1), MET-097 (monthly GLP-1, Phase 2), oral GLP-1 candidates, and preclinical nutrient-stimulated hormone therapeutics. Pfizer's strategic thesis is clear: build a full obesity portfolio spanning injectable and oral formats, monthly and daily dosing, GLP-1 and amylin mechanisms.

MET-233's monthly dosing interval, if validated, would address a different market segment than weekly injectables: patients who prefer minimal injection frequency and are willing to trade peak efficacy for convenience.

5.0 What Went Wrong the First Time

The amylin investment thesis cannot be evaluated without understanding why it failed before.

The first generation of amylin therapeutics — pramlintide, davalintide, and their predecessors — failed for specific, addressable reasons. Understanding those reasons is critical because it determines whether the current pipeline has actually solved the problems or is repeating them with better marketing.

Pramlintide (Symlin): The Commercial Failure

Pramlintide was approved in 2005 and demonstrated the core amylin mechanism: appetite suppression, gastric emptying delay, glucagon suppression. But the product was designed for diabetes management, not obesity. The label required three daily injections before meals. Nausea rates exceeded 30%. Weight loss was modest (2-3 kg). The drug was expensive relative to its incremental benefit, and the dosing burden was prohibitive for adherence.

The fundamental error was not the mechanism but the molecule. Pramlintide is a minimally modified analog of native human amylin — three proline substitutions to prevent aggregation, with essentially no engineering for half-life extension, potency optimization, or tolerability. It was a proof-of-concept molecule brought to market as a finished product.

The result: peak revenue of approximately $100 million/year, eventually discontinued. The patents expired between 2013-2019 with no generic competition — because no one wanted to make a generic of a failed drug.

Davalintide: The Clinical Failure

Davalintide (AC-2307), also from Amylin Pharmaceuticals, was a second-generation amylin analog designed for obesity. It entered Phase 2 in the late 2000s but was discontinued due to an unfavorable efficacy-to-safety ratio. The drug produced less weight loss than expected relative to its side effect burden.

The lesson: pure amylin monotherapy, without combination strategy or significant tolerability engineering, hits a ceiling where the nausea-to-weight-loss ratio becomes unacceptable. The current generation addresses this by either combining amylin with GLP-1 (synergistic efficacy) or engineering selectivity profiles that reduce GI burden (petrelintide's placebo-like tolerability).

BI-473494: Zealand's Learning Curve

Zealand Pharma developed BI-473494, an early amylin agonist that was discontinued due to insufficient efficacy. But Zealand applied the learnings to develop petrelintide — which now has a $5.3 billion deal with Roche. The trajectory from BI-473494 to petrelintide illustrates that the problem was not amylin biology but amylin drug design. Zealand's second attempt, with better acylation chemistry and dose optimization, produced a drug with radically different clinical characteristics.

The Pattern

Every first-generation amylin failure shares the same root causes: short half-life requiring inconvenient dosing, inadequate tolerability engineering, and insufficient efficacy as a monotherapy. The current generation has addressed all three:

The failures taught the field what doesn't work. The current pipeline is built on those lessons.

6.0 Follow the Money

More than $19 billion in amylin-related deal value has been committed since 2024. The pace is not just accelerating — it is approaching the scale of the GLP-1 deal wave that reshaped the pharmaceutical industry between 2023 and 2025.

Total confirmed external deal value: $19.8 billion+

The Pfizer/Metsera deal is the headline. Originally structured at $4.9 billion, a bidding war with Novo Nordisk drove the final price to $10 billion — the largest pure obesity-focused acquisition in history. Metsera's pipeline centers on MET-233, a monthly amylin analog in Phase 1, plus MET-097, a monthly GLP-1 agonist in Phase 2. Pfizer's willingness to pay $10 billion for a Phase 1 amylin asset (alongside the GLP-1 program) tells you everything about how pharma values the mechanism.

The Roche/Zealand deal is the most strategically sophisticated. Roche didn't just buy petrelintide; it structured a co-development and co-commercialization agreement that pairs petrelintide with CT-388, Roche's own GLP-1/GIP dual agonist. The thesis: petrelintide's best-in-class tolerability combined with CT-388's multi-agonist efficacy creates a product that could match or exceed CagriSema with fewer side effects. The $1.65 billion upfront (including a $250 million signing bonus) plus $3.65 billion in milestones values petrelintide as a potential franchise, not just a Phase 2 asset.

The AbbVie/Gubra deal is notable for what it reveals about the risk appetite. AbbVie committed $2.2 billion for a Phase 1 DACRA — before any controlled efficacy data existed. The Phase 1 MAD results (7.75-9.79% weight loss at 12 weeks) were reported after the deal closed, validating AbbVie's bet. But the deal was made on preclinical data and mechanism-of-action conviction alone.

Pfizer's second amylin deal (Sciwind/Verdiva, ~$2.5 billion total potential) adds VRB-102 (subcutaneous amylin agonist) and VRB-103 (oral amylin agonist) — both preclinical. Pfizer is building a portfolio approach across multiple amylin modalities, hedging format risk (injectable vs. oral) and timeline risk (Phase 1 vs. preclinical).

6.1 What the Deals Reveal

The deal economics expose three critical patterns.

First, amylin valuations are escalating faster than clinical data can justify on traditional metrics. AbbVie paid $2.2 billion for a Phase 1 drug with no controlled efficacy data. Roche paid $5.3 billion for a Phase 2 drug with moderate (10.7%) monotherapy weight loss. Pfizer paid $10 billion for a Phase 1 amylin analog bundled with a Phase 2 GLP-1. These valuations are not priced on current data. They are priced on the belief that amylin is essential to the next generation of obesity therapy and that building internally would take too long.

Second, every major pharma company has now placed at least one amylin bet. Novo (CagriSema, cagrilintide, amycretin, three more), Lilly (eloralintide), Roche (petrelintide), Pfizer (Metsera + Sciwind), AbbVie (Gubra), AstraZeneca (AZD6234). The only top-10 pharma company without a disclosed amylin program is Merck. This level of industry alignment on a single mechanism has not occurred since GLP-1 itself.

Third, the deal window for unpartnered programs is narrowing. Of the 40 programs in development, the majority of Phase 2+ assets are now partnered or internal to large pharma. The most notable unpartnered programs are at KeyBioscience (KBP-042, KBP-336), Structure Therapeutics (ACCG-2671, ACCG-3535), and Viking Therapeutics (DACRA). For BD teams, the window to acquire amylin programs at reasonable valuations is closing. CagriSema's FDA decision and the subsequent data readouts in 2026-2027 will either compress or expand that window, depending on outcomes.

7.0 How Good Are They?

The efficacy data across the amylin landscape is diverse — spanning pure monotherapy to triple-combination approaches, injectable peptides to oral formulations, 12-week Phase 1 readouts to 68-week Phase 3 results. Direct cross-trial comparison is imprecise. But the broad patterns are meaningful.

Several observations stand out.

Eloralintide's 20.1% at 48 weeks as a pure amylin monotherapy is the single most important data point in the landscape. It demonstrates that amylin alone — without any GLP-1 component — can deliver weight loss in the range that GLP-1 monotherapy achieves. This means amylin is not merely an "add-on" mechanism. It is a standalone obesity mechanism that can compete with GLP-1 head-to-head. This fundamentally changes the strategic calculus for every pharma company: you don't need amylin just for combinations. You need it as an alternative for the millions of patients who can't tolerate GLP-1s.

CagriSema's 20.4% at 68 weeks confirms the combination thesis: GLP-1 + amylin exceeds what either mechanism achieves alone. The approximately 5-8 percentage point incremental benefit of adding amylin to semaglutide is consistent across Phase 2 and Phase 3 data.

Amycretin's oral formulation data (10.1% at 36 weeks in T2D patients) is the earliest signal that an oral GLP-1/amylin combination can work. The number itself is modest, but the format — a daily pill targeting both pathways — is the product that could ultimately capture the largest market share.

Petrelintide's 10.7% at 42 weeks is the weakest efficacy number in the Phase 2+ tier, but its tolerability profile is in a class by itself. If the combination with Roche's CT-388 can push efficacy above 20% while maintaining the placebo-like safety, petrelintide becomes the tolerability play that wins the long game. The relevant comparison is not petrelintide monotherapy versus CagriSema, but petrelintide + CT-388 versus CagriSema.

ABBV-295's 9.79% at 12 weeks in Phase 1 is a steep early trajectory. Extrapolating Phase 1 data is unreliable, but the dose-response curve suggests significant room for further weight loss at higher doses and longer durations.

7.1 Tolerability as the Differentiator

If efficacy continues to converge as more programs mature, tolerability may be what separates the winners.

The amylin mechanism carries an inherent tolerability challenge. Amylin signals through the area postrema, the same brainstem region that triggers nausea and vomiting. Higher receptor activation drives more appetite suppression but also more GI side effects. The first-generation drugs (pramlintide) hit this ceiling hard.

Selectivity. Eloralintide's 50-100x selectivity for AMYR over CALCR is designed to minimize calcitonin-related effects (C-cell stimulation, thyroid concerns) while preserving appetite suppression. Petrelintide achieves a similar outcome through its specific acylation chemistry: AMYR modulation with minimal CALCR activation.

Dose optimization. ZUPREME-1 demonstrated that the right dose of petrelintide can produce meaningful weight loss with zero vomiting — a tolerability profile that no GLP-1 or amylin drug has previously achieved. This suggests the tolerability problem is dose-dependent and solvable, not mechanism-inherent.

Combination dilution. In CagriSema, each component (cagrilintide and semaglutide) is dosed at levels below their individual maximum tolerated doses. The combination achieves higher efficacy than either component alone at its administered dose, because the mechanisms are synergistic. This means the GI burden per unit of weight loss is potentially lower in the combination than in either monotherapy.

The tolerability race is not just about which drug has fewer side effects. It's about which drug has the best efficacy-to-tolerability ratio. A drug that delivers 20% weight loss with 5% discontinuation (petrelintide + CT-388 thesis) beats a drug that delivers 23% weight loss with 15% discontinuation (CagriSema's potential profile) for the majority of patients, physicians, and payers.

8.0 The Patent Question

Every analysis of the amylin race covers the same dimensions: clinical phase, weight-loss percentage, deal size, combination strategy. These are important. They are also visible to everyone.

The dimension that remains opaque to most public market investors is the patent architecture protecting each program. When multiple amylin programs deliver comparable efficacy in combination with GLP-1 agonists, the competitive moat shifts from "my drug works better" to "my drug is protected by broad patent claims, layered secondary filings, and a defensive thicket that delays generic entry by a decade."

8.1 What We Know

The amylin patent landscape is narrower than GLP-1 — approximately 8-12 major patent families in active development, compared to 100+ for GLP-1 agonists — but the strategic stakes per family are higher because the competitive set is smaller.

Petrelintide has the strongest disclosed IP position in the amylin space. Composition-of-matter protection through 2037, extendable to 2042 with patent-term extension. This gives Zealand/Roche a decade of runway beyond CagriSema's semaglutide component expiry. For a drug that may not reach market until 2029-2030, protection through 2042 provides 12-13 years of exclusivity — more than enough for franchise economics.

CagriSema's patent position is more complex than it appears. The combination is patented, and cagrilintide has its own protection. But semaglutide's core patent expires in December 2031. When generic semaglutide arrives, a biosimilar version of the semaglutide component could theoretically be combined with cagrilintide (or a cagrilintide biosimilar, depending on its own patent timeline) to create a comparable product. The combination patent and cagrilintide's independent patent provide protection, but the semaglutide clock introduces vulnerability that does not exist for standalone amylin programs.

The oral small-molecule amylin space is largely unpatented. ACCG-2671 and its backup ACCG-3535 are first movers in a category with minimal prior art. Structure Therapeutics likely has composition-of-matter patents filed (given the December 2025 Phase 1 initiation), but the full portfolio is not yet disclosed. For new entrants (Viking's small-molecule DACRA, Alveus Therapeutics), the oral amylin space represents significant white space for IP positioning — similar to where the oral GLP-1 space was in 2018-2019 before the current explosion of filings.

8.2 The Amgen v. Sanofi Shadow

The Supreme Court's 2023 ruling in Amgen v. Sanofi raised the enablement bar for biological patent claims. Broad genus claims covering families of molecules must now demonstrate that the patent teaches a person skilled in the art how to make and use the full scope of the claimed genus — not just the specific examples disclosed. This ruling affects every amylin peptide patent in the landscape.

For programs like petrelintide, eloralintide, and cagrilintide — each protected by specific peptide composition-of-matter patents with detailed structural characterization — the impact may be manageable. The claims are relatively narrow (covering specific acylated analogs with defined sequences), and the synthetic methodology is well-disclosed.

For broader genus claims covering "amylin analogs with modifications at positions X, Y, Z," the enablement challenge is more significant. Any amylin patent holder with broad Markush-style claims faces post-Amgen scrutiny that could narrow the effective scope of protection.

8.3 Where the White Space Is

• Oral small-molecule amylin agonists. ACCG-2671 is first-to-file, but the broader chemical space for small-molecule AMYR/CALCR agonism is largely unexplored from an IP perspective.
• Specific dual/triple combinations. While GLP-1 + amylin is well-covered (Novo Nordisk), combinations of amylin with GIP agonists, glucagon agonists, SGLT2 inhibitors, or other mechanisms may have available IP space.
• Biased amylin signaling. Selectivity between AMY1R, AMY2R, and AMY3R subtypes — and the resulting differential effects on appetite, glucose, and side effects — is an emerging area where IP filings are sparse.
• Monthly and extended-dosing formulations. MET-233's monthly dosing represents a novel formulation approach. Long-acting depot formulations and implantable amylin delivery systems are largely unpatented.

9.0 The Standard of Care — and What Comes After

Understanding where amylin fits requires understanding the current treatment landscape it is entering.

As of early 2026, the obesity standard of care is in the middle of a generational transformation. The ADA's updated guidelines (January 2026) reflect a field that has moved from viewing obesity as a behavioral problem to treating it as a chronic disease requiring pharmacotherapy.

The market is dominated by GLP-1 agonists. Tirzepatide and semaglutide together account for the vast majority of new prescriptions. The remaining older agents (Contrave, Qsymia, phentermine) are increasingly relegated to second-tier or bridge therapy roles.

But the current landscape has three structural limitations that amylin directly addresses:

The efficacy ceiling. GLP-1 monotherapy plateaus at approximately 15-17% weight loss. Tirzepatide (which adds GIP agonism) extends this to 22.5%. But for the subset of patients who need 25%+ weight loss to reach metabolic health — estimated at 15-20 million Americans — current options are insufficient. CagriSema's 20.4% and the potential for triple-mechanism products (GLP-1 + GIP + amylin) represent the first credible path to 25-30% weight loss without surgery.

The tolerability wall. GLP-1 agonists cause nausea in 20-40% of patients and vomiting in 10-25%. These rates have improved with slower titration but remain the primary reason patients discontinue therapy. Amylin agonists with engineered tolerability (petrelintide) offer an alternative mechanism for patients who cannot tolerate GLP-1s — estimated at 10-20% of the treated population, or 500,000-1,000,000 current patients.

The oral gap. The approved orals (oral semaglutide, orforglipron pending) target GLP-1 alone. There is currently no approved oral combination targeting both GLP-1 and amylin. Amycretin's oral formulation and ACCG-2671's oral small-molecule approach represent the first attempts to close this gap. The combination oral market — a daily pill that activates two or three appetite-suppression pathways — is potentially the largest unaddressed segment in obesity pharmacotherapy.

9.1 Where Amylin Fits in the Treatment Algorithm

Amylin is not replacing GLP-1. It is being integrated into an expanding treatment algorithm:

Tier 1 (First-Line): Oral GLP-1 agonists (orforglipron, oral semaglutide) for primary care. Low barrier to prescribing. 12-16% weight loss.

Tier 2 (Intensification): Injectable GLP-1 or GLP-1/GIP (semaglutide, tirzepatide) for patients needing more efficacy. 15-22% weight loss. Weekly injection.

Tier 3 (Combination): GLP-1 + amylin combinations (CagriSema, amycretin, petrelintide + CT-388) for inadequate responders to Tier 2. 22-28% weight loss. This is the tier amylin is creating.

Tier 4 (Alternative Mechanism): Pure amylin monotherapy (eloralintide) for patients intolerant to GLP-1. 15-20% weight loss. Different mechanism, different side-effect profile.

Tier 5 (Future): Oral combination pills (oral amylin + oral GLP-1), triple agonists (GLP-1 + GIP + amylin), and monthly injectables (MET-233 + MET-097). The convenience frontier.

This tiered algorithm means amylin doesn't need to beat GLP-1 to succeed. It needs to be the answer when GLP-1 alone isn't enough — and the clinical data says that's 15-25% of treated patients, a multi-billion-dollar segment.

10.0 The Next Eighteen Months

The amylin landscape will look fundamentally different by the end of 2027. The next eighteen months contain more catalysts than the previous five years combined.

Every one of these events will reshape competitive positioning, deal activity, and investor attention.

10.1 The Semaglutide Patent Cliff

The timeline for generic competition is already set. Semaglutide's core composition-of-matter patent expires in December 2031. When generic semaglutide arrives, it creates both risk and opportunity for the amylin space.

Risk: CagriSema contains semaglutide. Generic semaglutide availability could enable biosimilar combinations that undercut CagriSema's pricing, particularly if cagrilintide's own patent protection is limited.

Opportunity: Programs with standalone amylin patents (petrelintide through 2042, eloralintide through the late 2030s) will be the only premium-priced options standing after the semaglutide cliff. A world with generic semaglutide and patented amylin creates a market where the amylin component becomes the primary source of exclusivity and pricing power.

This dynamic is the hidden thesis behind the Roche/Zealand deal. By pairing petrelintide (the longest-protected amylin asset) with CT-388 (Roche's proprietary GLP-1/GIP agonist), Roche is building a combination that maintains patent protection on both components well beyond 2031. When CagriSema loses its semaglutide exclusivity, petrelintide + CT-388 will still be fully protected.

10.2 The Oral Amylin Frontier

The most consequential long-term catalyst may not be any of the injectable programs. It may be whether oral small-molecule amylin agonists work.

Structure Therapeutics' ACCG-2671 Phase 1 data (expected H2 2026) will be the first answer. If the safety, pharmacokinetic, and preliminary efficacy signals are positive, oral amylin enters the same trajectory that oral small-molecule GLP-1 agonists followed from 2021 to 2026 — a five-year path from Phase 1 to market that could reshape the competitive landscape by 2030.

An oral amylin pill combined with an oral GLP-1 pill — a fixed-dose daily combination targeting both pathways without injection — would be the ultimate primary-care obesity product. Manufacturing cost under $15/month. Room temperature stable. No needle. No fasting. No refrigeration. The GLP-1 Pulse Report (Report #1) described oral small-molecule GLP-1 agonists as the platform that could reach the 95% of patients that injectables can't. Oral amylin could do the same for the combination market.

This is still speculative. ACCG-2671 is in Phase 1. The clinical path from first-in-human to approval is long and uncertain. But the structural economic argument — oral small molecules at $5-15/month COGS versus injectable peptides at $50-100/month — is the same argument that drove $47 billion in oral GLP-1 deal activity. The oral amylin deal wave hasn't started yet.

PV Pulse is published by PatentVest. For questions, licensing inquiries, or to discuss IP strategy for your portfolio, contact us.

PatentVest Pulse is published by PatentVest.